No Carolina / New York / Florida        Ph: 561.316.3330

HomeACQUISITIONS and MERGERSAcquisition of Vigilenz Completed Reports Bactiguard

Acquisition of Vigilenz Completed Reports Bactiguard

What To Know

  • The Bactiguard Board of Directors has approved the transaction and shareholders including Christian Kinch, Thomas von Koch, Jan Ståhlberg, The Fourth Swedish National Pension Fund (AP4) and Nordea Investment Funds, together representing approximately 66 percent of the capital and 84 percent of the votes in Bactiguard have declared that they will support the issuance of new class B-shares at the AGM.
  • The remaining part of the consideration, 241 512 new class B-shares in Bactiguard, is subject to approval by the annual general meeting of shareholders in Bactiguard on 28 April 2020.

March 2, 2020

Acquisition of Vigilenz was announced on February 4, 2020.

All conditions precedent have been fulfilled and the first part of the total consideration, consisting of a cash payment of USD 4.5 million, has been paid. The remaining part of the consideration, 241 512 new class B-shares in Bactiguard, is subject to approval by the annual general meeting of shareholders in Bactiguard on 28 April 2020.

The cash portion has been financed through bank facilities provided by Skandinaviska Enskilda Banken (SEB), with a term of three years. At the same time, the term of Bactiguard’s current bank facility with SEB has been extended by the same tenor.

The Bactiguard Board of Directors has approved the transaction and shareholders including Christian Kinch, Thomas von Koch, Jan Ståhlberg, The Fourth Swedish National Pension Fund (AP4) and Nordea Investment Funds, together representing approximately 66 percent of the capital and 84 percent of the votes in Bactiguard have declared that they will support the issuance of new class B-shares at the AGM.

The newly acquired companies will be consolidated in Bactiguard’s financial accounts from March 2020. At the same time, the integration of the companies has been initiated, which means, among other things, that the product portfolios will be sold through both companies’ distribution networks.

By using this website you agree to accept Medical Device News Magazine Privacy Policy